Pharmaceutical Technology, November 2011 Issue (PDF)

Publication
Article
Pharmaceutical TechnologyPharmaceutical Technology-11-02-2011
Volume 35
Issue 11

Click the title above to open the Pharmaceutical Technology November 2011 issue in an interactive PDF format.

External Link - PharmTech_NA_Nov2011.pdf

Articles in this issue
i1-747442-1408610138783.jpg
Growth for Small Pharma
i1-747434-1408610160178.jpg
Drug Shortages Create Crisis for Manufacturers, Regulators
Using Simulation to Improve Drug-Delivery Effectiveness
Using Simulation to Improve Drug-Delivery Effectiveness
Easy on the Alcohol!
i4-747436-1408610151888.gif
Catalyzing the Synthesis
i1-747444-1408610134593.jpg
Super Fast Pharma
Global Healthcare on the Ground: Novartis Focuses on Treating Rare Diseases
Managing the Global Clinical-Trial Material Supply Chain
Managing the Global Clinical-Trial Material Supply Chain
i3_t-747439-1408610144422.jpg
In the Spotlight November 2011
i4-747441-1408610140779.jpg
Biosimilars' Technology Needs
i17_t-747429-1408610177520.gif
Near Infrared Analysis of Tablets Containing Two Active Ingredients
i8_t-747432-1416910870018.jpg
Water-Intrusion Test Integration
i1-747440-1408610142892.jpg
Passion, Innovation, and Loss
i2-747435-1408610156645.gif
PQRI Case Study (5): Nonsterile Facility Cleaning Requirements
Report from Russia
Report from Russia
Recent Videos
Drug Digest: Strategic Partnerships
Michelle Bridenbaker from Unbiased Science discusses her thoughts on the key industry from 2024 and those she anticipates will impact the industry in 2025 and beyond.
Henny Zijlstra from Adragos Pharma chats about the trends affecting the outsourcing market, various strategies being employed by service providers, and the value of end-to-end services.
Related Content
TOP NEWS on grunge world map | Image Credit: © Sean K - © Sean K - stock.adobe.com

FDA CBER Director Peter Marks Resigns

Susan Haigney
March 31st 2025
Article

Marks called out an ‘assault’ on truth and science in his resignation letter, which has sent the bio/pharmaceutical industry reeling.

Site Logo

Transformations in Drug Development for Cell and Gene Therapies

PPD;Thermo Fisher Scientific
March 28th 2025
Podcast

As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com

EMA Recommends Five New Medicines for Approval

Patrick Lavery
March 28th 2025
Article

Three of the five are biosimilars, and seven additional medicines received recommendations for indication extensions.

Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang

Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang

PPD;Thermo Fisher Scientific
March 28th 2025
Podcast

As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com

Novotech Named Best Australian CRO at Asia-Pacific Biopharma Excellence Awards

Patrick Lavery
March 28th 2025
Article

Winners are selected entirely through industry voting, with those honored representing recognition by their peers.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

FDA Issues Warning Letter to Aspen Biopharma Labs for API Manufacturing Deviations

Feliza Mirasol
March 27th 2025
Article

In the latest of a series of warning letters to India-based API manufacturers, FDA issued a warning letter to Aspen for deviations in CGMP in the production of APIs.